GO
Loading...

Salix Pharmaceuticals Ltd

More

  • March 16- U.S. stocks rallied on Monday as the U.S. dollar eased back from its recent peak and worries eased about the timing of a Federal Reserve interest rate hike. The S&P healthcare sector led gains in the S&P 500. It jumped 2.2 percent, helped by a 5.7 percent price increase in shares of Amgen to $163.03, following promising data in studies of a new class of...

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed higher as investors cheered a pause in the dollar rally and eyed renewed weakness in oil prices ahead of Wednesday's Fed meeting.

  • "It's just a little bit of relief from last week's selloff," said Joseph Benanti, managing director, sales and trading of Rosenblatt Securities in New York. The S&P healthcare sector was up 1.9 percent, helped by a 3.6 percent price increase in shares of Amgen to $159.73, following promising data in studies of a new class of cholesterol-reducing drugs.

  • *Empire State manufacturing data miss estimates. "It's just a little bit of relief from last week's selloff," said Joseph Benanti, managing director, sales and trading of Rosenblatt Securities in New York. Until Fed Chair Janet Yellen's statement on Wednesday afternoon, Benanti is expecting light volume.

  • *Empire State manufacturing data misses estimates. March 16- U.S. stocks opened higher Monday and the benchmark S&P 500 rebounded after three weeks of losses as the euro strengthened against the dollar, easing some concerns over the impact of a robust greenback on corporate earnings. A recovery in the euro was reassuring investors, said Nick Colas, chief market...

  • US STOCKS-Wall St futures rise as euro recovers Monday, 16 Mar 2015 | 9:02 AM ET

    *Empire State manufacturing data miss estimates. March 16- U.S. stock index futures were up on Monday, putting the benchmark S&P 500 on track for a rebound after three weeks of losses, as currency markets helped reassure U.S. investors concerned about how a strong dollar would hurt earnings. A recovery in the euro was reassuring investors as a rapidly rising U.S....

  • Valeant, Salix agree to cash deal of $173 a share Monday, 16 Mar 2015 | 7:56 AM ET
    Valeant Pharmaceuticals sign at the company's headquarters in Mississauga, Ontario.

    Valeant Pharmaceuticals agreed to buy Salix Pharmaceuticals for $173 per share Monday morning.

  • Valeant won't overpay for Salix: Bill Ackman Friday, 13 Mar 2015 | 12:33 PM ET
    Valeant Pharmaceuticals International’s headquarters in Mississauga, Ontario, Canada, is shown in this March 30, 2011 photo.

    Valeant chief Michael Pearson won't pay too much for Salix, which earlier this week received a competing offer from Endo, Bill Ackman tells CNBC.

  • March 12- Endo International Plc's $11 billion offer this week for Salix Pharmaceuticals Ltd, an effort to trump an agreed $10 billion bid from Valeant Pharmaceutical Inc, illustrates CEO Rajiv De Silva's plan to be seen as not just a protege of Valeant chief Mike Pearson, but as a challenger. If successful, buying Raleigh, North Carolina- based Salix would combine...

  • Traders on the floor of the New York Stock Exchange.

    U.S. stocks closed mildly lower on amid continued concern over dollar gains and the timing of a Fed interest rate hike.

  • Ackman's $20 billion Pershing Square Capital Management hedge fund began building up the $3.3 billion stake, only months after its vocal effort to help Valeant buy Botox-maker Allergan failed, a source familiar with the investment told Reuters. His Pershing Square has notched big wins at railway firm Canadian Pacific and shopping mall operator General...

  • Ackman's $20 billion Pershing Square Capital Management began building up the 5 percent stake in the Canadian drug maker this year, only months after his vocal effort to help Valeant buy Botox-maker Allergan failed. His Pershing Square has notched big wins at railway Canadian Pacific and shopping mall operator General Growth Properties, and also made money...

  • LONDON, March 5- AbbVie's $21 billion deal to buy Pharmacyclics shows big pharma's hunger for new drugs at a time when research at smaller biotechnology companies is driving some of the most promising advances in medicine. AbbVie's planned purchase of Pharmacyclics is the largest global pharmaceutical deal of 2015 to date and takes M&A activity in the sector...

  • March 5- AbbVie Inc is to buy Pharmacyclics Inc for about $21 billion, giving it access to what is expected to be one of the world's top-selling cancer drugs and expanding its reach in the profitable oncology field. AbbVie will pay $261.25 per share in cash and stock, a 13 percent premium to Pharmacyclics stock's closing price on Wednesday. Deutsche Bank analyst...

  • *AbbVie to pay $261.25 per share in cash and stock. The deal gives AbbVie access to Pharmacyclics' cancer drugs portfolio, lessening the Chicago- based company's dependence on its rheumatoid arthritis drug Humira that accounts for most of its sales. "Imbruvica is not only complementary to AbbVie's oncology pipeline, it has demonstrated strong clinical...

  • J&J nears deal for cancer drugmaker Wednesday, 4 Mar 2015 | 5:06 PM ET
    Johnson & Johnson hospital-grade gauze pads are displayed at a Target store in Rosemont, Ill.

    Johnson & Johnson is nearing a deal to acquire U.S. cancer drugmaker Pharmacyclics.

  • After-hours buzz: Caesars, Palo Alto, Mylan & more Monday, 2 Mar 2015 | 5:20 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Check out which companies are making headlines after the bell Monday: Caesars, Palo Alto, Mylan & more.

  • Traders work the floor of the New York Stock Exchange.

    U.S. stocks closed higher, with the Nasdaq above the psychologically key level of 5,000 for the first time since March 2000 and the Dow at a record.

  • Wall Street takes stock of China rate cut Monday, 2 Mar 2015 | 8:43 AM ET

    U.S. stock index futures pointed to a flat to slightly higher open on Wall Street as investors reacted to overseas markets and a rate cut in China.

  • Cramer Remix: Where's the Nasdaq bubble? Monday, 23 Feb 2015 | 7:02 PM ET
    Jim Cramer on the set of Mad Money

    As Apple hits new highs, "Mad Money" host Jim Cramer is betting on it to lift the Nasdaq.